Literature DB >> 9649979

Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.

T Carnwath1, J Hardman.   

Abstract

This study compares the clinical response to lofexidine and clonidine in the out-patient treatment of opiate withdrawal in 50 opiate addicts, using a randomised double-blind study design. Patients were taking 40 mg or less methadone daily, or equivalent amounts of other opiates. Fifty-eight percent of those starting treatment completed detoxification, and were opiate free at 4 weeks: more patients completed withdrawal in the lofexidine group, but the difference was not significant. Clonidine produced more hypotensive effects: more home visits were also required by medical staff. There was no other significant difference in side effects. Both drugs can be used successfully in out-patient detoxification, but lofexidine is more economical in regard to staff time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649979     DOI: 10.1016/s0376-8716(98)00040-4

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  16 in total

Review 1.  Opioid dependence.

Authors:  Jacinta O'Shea; Fergus Law; Jan Melichar
Journal:  BMJ Clin Evid       Date:  2009-07-24

Review 2.  Opioid dependence.

Authors:  K Thyarappa Praveen; Fergus Law; Jacinta O'Shea; Jan Melichar
Journal:  BMJ Clin Evid       Date:  2011-09-20

Review 3.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

Review 4.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

Review 5.  Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking.

Authors:  J Stewart
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

6.  The impact of lofexidine on stress-related opioid craving and relapse: Design and methodology of a randomized clinical trial.

Authors:  Constance Guille; Courtney King; Viswanathan Ramakrishnan; Nathaniel Baker; Bernadette Cortese; Lisa Nunn; Taylor Rogers; Aimee McRae-Clark; Kathleen Brady
Journal:  Contemp Clin Trials       Date:  2021-11-02       Impact factor: 2.226

Review 7.  Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Authors:  Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Authors:  Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman
Journal:  Drug Alcohol Depend       Date:  2008-05-27       Impact factor: 4.492

Review 9.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

Review 10.  A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms.

Authors:  Ivan Urits; Anjana Patel; Robbie Zusman; Celina Guadalupe Virgen; Mohammad Mousa; Amnon A Berger; Hisham Kassem; Jai Won Jung; Jamal Hasoon; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2020-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.